Intel CEO Lip-Bu Tan has reaffirmed the company's commitment to Elon Musk’s Terafab project today, addressing investor concerns regarding potential competition from TSMC. The partnership, which relies on Intel’s 14A process technology for large-scale AI chip production, remains a central piece of the chipmaker’s foundry turnaround strategy.
Intel Corporation has officially confirmed that it remains a core partner in Elon Musk’s Terafab project. The statement from CEO Lip-Bu Tan on October 7, 2026, comes as a direct response to recent market uncertainty caused by reports that Elon Musk is in preliminary discussions with TSMC regarding potential cooperation on the same project.
Terafab is a significant industrial initiative backed by Tesla, SpaceX, and xAI, aimed at establishing massive semiconductor manufacturing capacity in Texas. For Intel, the collaboration is not just another contract; it involves the deployment of the company's advanced 14A process technology. This technology is intended to power the high-performance AI and robotics chips central to the Terafab vision.
While Intel has served as the sole named chip partner for the initiative since April 2026, the potential entry of TSMC has created market anxiety. Investors have reacted with caution, leading to recent volatility in Intel’s stock price. The core concern for the market is that if TSMC enters the fold, Intel’s influence, manufacturing volume, and strategic value within the Terafab project could be diluted.
This partnership is critical for Intel’s broader financial goals. The company is currently executing a major turnaround in its foundry business, which seeks to move beyond manufacturing chips only for its own products to becoming a major supplier for external customers. The success of this turnaround relies heavily on securing and retaining high-profile clients like the Musk-led ventures. Without these large-scale wins, the path to improving foundry margins and financial health becomes steeper.
Beyond the competitive risks, the Terafab project itself remains an unprecedented industrial effort. The scale and technical complexity involved mean that any delay or failure to meet production targets could create operational pressure for all involved partners. Investors are now closely watching for further official announcements regarding the structure of the partnership, the confirmation of specific production milestones, and any clarity on whether multiple chipmakers will ultimately share the manufacturing load. For now, the continuity of the Intel-Terafab relationship stands as a vital, albeit scrutinized, pillar of the company’s current business strategy.